(PRE) Prenetics Global - Overview
Exchange: NASDAQ •
Country: Hong Kong •
Currency: USD •
Type: Common Stock •
ISIN: KYG722451062
Stock: Genetic Tests, Wellness Supplements, Sports Nutrition
Total Rating 45
Risk 35
Buy Signal 0.91
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 105% |
| Relative Tail Risk | -18.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.73 |
| Alpha | 260.14 |
| Character TTM | |
|---|---|
| Beta | -0.106 |
| Beta Downside | 0.407 |
| Drawdowns 3y | |
|---|---|
| Max DD | 87.02% |
| CAGR/Max DD | -0.06 |
Description: PRE Prenetics Global January 20, 2026
Prenetics Global Ltd (NASDAQ:PRE) is a Hong Kong-based health-sciences firm that operates consumer-facing brands in genetics, wellness, and sports nutrition. It markets health-and-wellness products under the IM8 brand, distributes sports-nutrition items for the Europa brand, and runs CircleDNA, a direct-to-consumer genetic-testing service powered by next-generation sequencing (NGS). Founded in 2014, the company’s footprint spans Hong Kong, the United States, and other international markets.
Key metrics and sector dynamics to watch: (1) CircleDNA’s test volume grew ~45 % YoY in Q3 2024, reflecting rising consumer interest in personalized health; (2) the global consumer genetics market is projected to reach $13 bn by 2027, driven by decreasing sequencing costs and greater health-data awareness; (3) Prenetics’ revenue mix is roughly 55 % genetics, 30 % wellness products, and 15 % distribution services, making its exposure to regulatory shifts in genetic testing a material risk factor.
For a deeper quantitative analysis, you might explore ValueRay’s data platform to benchmark Prenetics against peers and assess valuation sensitivities.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -52.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -9.01 > 1.0 |
| NWC/Revenue: 20.89% < 20% (prev 77.47%; Δ -56.58% < -1%) |
| CFO/TA -0.15 > 3% & CFO -28.9m > Net Income -52.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.9m) vs 12m ago 9.22% < -2% |
| Gross Margin: 46.80% > 18% (prev 0.55%; Δ 4625 % > 0.5%) |
| Asset Turnover: 28.78% > 50% (prev 10.84%; Δ 17.94% > 0%) |
| Interest Coverage Ratio: -182.7 > 6 (EBITDA TTM -42.5m / Interest Expense TTM 277.3k) |
Altman Z'' -4.92
| A: 0.07 (Total Current Assets 38.3m - Total Current Liabilities 25.3m) / Total Assets 196.5m |
| B: -2.63 (Retained Earnings -517.1m / Total Assets 196.5m) |
| C: -0.23 (EBIT TTM -50.7m / Avg Total Assets 216.1m) |
| D: 4.57 (Book Value of Equity 161.3m / Total Liabilities 35.3m) |
| Altman-Z'' Score: -4.92 = D |
Beneish M -2.61
| DSRI: 0.06 (Receivables 1.79m/11.7m, Revenue 62.2m/25.6m) |
| GMI: 1.18 (GM 46.80% / 55.43%) |
| AQI: 1.19 (AQ_t 0.79 / AQ_t-1 0.67) |
| SGI: 2.43 (Revenue 62.2m / 25.6m) |
| TATA: -0.12 (NI -52.5m - CFO -28.9m) / TA 196.5m) |
| Beneish M-Score: -2.61 (Cap -4..+1) = A |
What is the price of PRE shares?
As of February 07, 2026, the stock is trading at USD 19.24 with a total of 193,705 shares traded.
Over the past week, the price has changed by +0.76%, over one month by +18.04%, over three months by +55.85% and over the past year by +255.64%.
Over the past week, the price has changed by +0.76%, over one month by +18.04%, over three months by +55.85% and over the past year by +255.64%.
Is PRE a buy, sell or hold?
Prenetics Global has received a consensus analysts rating of 5.00.
Therefore, it is recommended to buy PRE.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31 | 61.1% |
| Analysts Target Price | 31 | 61.1% |
| ValueRay Target Price | 22.8 | 18.4% |
PRE Fundamental Data Overview February 05, 2026
P/S = 4.2508
P/B = 2.0314
Revenue TTM = 62.2m USD
EBIT TTM = -50.7m USD
EBITDA TTM = -42.5m USD
Long Term Debt = 2.10m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.43m USD (from shortTermDebt, last quarter)
Debt = 2.10m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -11.2m USD (from netDebt column, last quarter)
Enterprise Value = 306.0m USD (327.6m + Debt 2.10m - CCE 23.7m)
Interest Coverage Ratio = -182.7 (Ebit TTM -50.7m / Interest Expense TTM 277.3k)
EV/FCF = -10.22x (Enterprise Value 306.0m / FCF TTM -29.9m)
FCF Yield = -9.78% (FCF TTM -29.9m / Enterprise Value 306.0m)
FCF Margin = -48.12% (FCF TTM -29.9m / Revenue TTM 62.2m)
Net Margin = -84.39% (Net Income TTM -52.5m / Revenue TTM 62.2m)
Gross Margin = 46.80% ((Revenue TTM 62.2m - Cost of Revenue TTM 33.1m) / Revenue TTM)
Gross Margin QoQ = 59.54% (prev 41.23%)
Tobins Q-Ratio = 1.56 (Enterprise Value 306.0m / Total Assets 196.5m)
Interest Expense / Debt = 2.61% (Interest Expense 55.0k / Debt 2.10m)
Taxrate = 21.0% (US default 21%)
NOPAT = -40.0m (EBIT -50.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.51 (Total Current Assets 38.3m / Total Current Liabilities 25.3m)
Debt / Equity = 0.01 (Debt 2.10m / totalStockholderEquity, last quarter 161.3m)
Debt / EBITDA = 0.26 (negative EBITDA) (Net Debt -11.2m / EBITDA -42.5m)
Debt / FCF = 0.37 (negative FCF - burning cash) (Net Debt -11.2m / FCF TTM -29.9m)
Total Stockholder Equity = 163.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.29% (Net Income -52.5m / Total Assets 196.5m)
RoE = -32.16% (Net Income TTM -52.5m / Total Stockholder Equity 163.3m)
RoCE = -30.63% (EBIT -50.7m / Capital Employed (Equity 163.3m + L.T.Debt 2.10m))
RoIC = -24.87% (negative operating profit) (NOPAT -40.0m / Invested Capital 160.9m)
WACC = 5.51% (E(327.6m)/V(329.8m) * Re(5.53%) + D(2.10m)/V(329.8m) * Rd(2.61%) * (1-Tc(0.21)))
Discount Rate = 5.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 7.10%
Fair Price DCF = unknown (Cash Flow -29.9m)
EPS Correlation: -75.36 | EPS CAGR: -12.16% | SUE: 0.03 | # QB: 0
Revenue Correlation: -7.85 | Revenue CAGR: -23.62% | SUE: 2.16 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.24 | Chg30d=+0.410 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=1.52 | Chg30d=+1.580 | Revisions Net=+1 | Growth EPS=+168.5% | Growth Revenue=+124.4%
P/B = 2.0314
Revenue TTM = 62.2m USD
EBIT TTM = -50.7m USD
EBITDA TTM = -42.5m USD
Long Term Debt = 2.10m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.43m USD (from shortTermDebt, last quarter)
Debt = 2.10m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -11.2m USD (from netDebt column, last quarter)
Enterprise Value = 306.0m USD (327.6m + Debt 2.10m - CCE 23.7m)
Interest Coverage Ratio = -182.7 (Ebit TTM -50.7m / Interest Expense TTM 277.3k)
EV/FCF = -10.22x (Enterprise Value 306.0m / FCF TTM -29.9m)
FCF Yield = -9.78% (FCF TTM -29.9m / Enterprise Value 306.0m)
FCF Margin = -48.12% (FCF TTM -29.9m / Revenue TTM 62.2m)
Net Margin = -84.39% (Net Income TTM -52.5m / Revenue TTM 62.2m)
Gross Margin = 46.80% ((Revenue TTM 62.2m - Cost of Revenue TTM 33.1m) / Revenue TTM)
Gross Margin QoQ = 59.54% (prev 41.23%)
Tobins Q-Ratio = 1.56 (Enterprise Value 306.0m / Total Assets 196.5m)
Interest Expense / Debt = 2.61% (Interest Expense 55.0k / Debt 2.10m)
Taxrate = 21.0% (US default 21%)
NOPAT = -40.0m (EBIT -50.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.51 (Total Current Assets 38.3m / Total Current Liabilities 25.3m)
Debt / Equity = 0.01 (Debt 2.10m / totalStockholderEquity, last quarter 161.3m)
Debt / EBITDA = 0.26 (negative EBITDA) (Net Debt -11.2m / EBITDA -42.5m)
Debt / FCF = 0.37 (negative FCF - burning cash) (Net Debt -11.2m / FCF TTM -29.9m)
Total Stockholder Equity = 163.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.29% (Net Income -52.5m / Total Assets 196.5m)
RoE = -32.16% (Net Income TTM -52.5m / Total Stockholder Equity 163.3m)
RoCE = -30.63% (EBIT -50.7m / Capital Employed (Equity 163.3m + L.T.Debt 2.10m))
RoIC = -24.87% (negative operating profit) (NOPAT -40.0m / Invested Capital 160.9m)
WACC = 5.51% (E(327.6m)/V(329.8m) * Re(5.53%) + D(2.10m)/V(329.8m) * Rd(2.61%) * (1-Tc(0.21)))
Discount Rate = 5.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 7.10%
Fair Price DCF = unknown (Cash Flow -29.9m)
EPS Correlation: -75.36 | EPS CAGR: -12.16% | SUE: 0.03 | # QB: 0
Revenue Correlation: -7.85 | Revenue CAGR: -23.62% | SUE: 2.16 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.24 | Chg30d=+0.410 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=1.52 | Chg30d=+1.580 | Revisions Net=+1 | Growth EPS=+168.5% | Growth Revenue=+124.4%